NCT07496567 A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
| NCT ID | NCT07496567 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | EyeBiotech Ltd. |
| Condition | Macular Degeneration |
| Study Type | INTERVENTIONAL |
| Enrollment | 960 participants |
| Start Date | 2026-04-15 |
| Primary Completion | 2028-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 960 participants in total. It began in 2026-04-15 with a primary completion date of 2028-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD. The goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.
Eligibility Criteria
The main inclusion criteria include but are not limited to the following: * Has treatment naive choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) including subfoveal, juxtafoveal and extrafoveal lesions or retinal angiomatous proliferations (RAP) and polypoidal choroidal vascularization (PCV) lesions in at least one eye (study eye) * The diagnosis of neovascular age-related macular degeneration (NVAMD) must have been made within 21 days prior to starting study treatment The main exclusion criteria include but are not limited to the following * Has uncontrolled blood pressure at screening * History of any prior macular laser photocoagulation in the study eye * History of uveitis in either eye * History of cataract surgery, minimally invasive glaucoma surgery, or Yttrium-Aluminium Garnet (Yag) laser capsulotomy in the study eye within 90 days before entering the study * Has uncontrolled glaucoma in the study eye * Active retinal disease other than the condition under investigation in the study eye * Has previously received anti- vascular endothelial growth factor (VEGF) therapy or other intravitreal (IVT) therapy in the study eye
Contact & Investigator
Medical Director
STUDY DIRECTOR
Merck Sharp & Dohme LLC
Frequently Asked Questions
Who can join the NCT07496567 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Macular Degeneration. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07496567 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07496567 currently recruiting?
Yes, NCT07496567 is actively recruiting participants. Visit ClinicalTrials.gov or contact EyeBiotech Ltd. to inquire about joining.
Where is the NCT07496567 trial being conducted?
This trial is being conducted at Mountain View, United States, Lemont, United States, Hagerstown, United States, Edina, United States and 5 additional locations.
Who is sponsoring the NCT07496567 clinical trial?
NCT07496567 is sponsored by EyeBiotech Ltd.. The principal investigator is Medical Director at Merck Sharp & Dohme LLC. The trial plans to enroll 960 participants.